Research Article

Formulation and In Vitro Evaluation of Ufasomes for Dermal Administration of Methotrexate

Table 2

% Cumulative amount of methotrexate permeated after 24 h (microgram MTX) and skin deposition (percentage MTX) from different vesicular formulations and from aqueous control solution.

MTX (μg)MTX (% age)

Aqueous control solution 5 . 0 6 ± 0 . 8 4 %13 ± 3
carbopol gel 1 2 . 5 ± 2 . 8 30 ± 5
UF-3 2 1 . 5 ± 4 . 5 43 ± 4
UF gel 2 9 . 5 5 ± 4 . 3 52 ± 6
UF suspension 1 9 . 5 5 ± 4 . 6 45 ± 5